Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Federal Trade Commission
Teva
Accenture
Healthtrust
Deloitte

Generated: August 19, 2019

DrugPatentWatch Database Preview

Patent: 8,329,179

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,329,179
Title:Death domain containing receptor 4 antibodies and methods
Abstract: The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR4, which may be agonists and/or antagonists of DR4 activity.
Inventor(s): Ni; Jian (Germantown, MD), Rosen; Craig A. (Laytonsville, MD), Pan; James G. (Toronto, CA), Gentz; Reiner L. (Belo Horizonte-MG, BR), Dixit; Vishva M. (Los Altos Hills, CA)
Assignee: Human Genome Sciences, Inc. (Rockville, MD) The Regents of the University of Michigan (Ann Arbor, MI)
Application Number:12/010,108
Patent Claims:see list of patent claims

Details for Patent 8,329,179

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Try a Free Trial Human Genome Sciences, Inc. (Rockville, MD) The Regents of the University of Michigan (Ann Arbor, MI) 2017-01-28 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Try a Free Trial Human Genome Sciences, Inc. (Rockville, MD) The Regents of the University of Michigan (Ann Arbor, MI) 2017-01-28 RX search
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Try a Free Trial Human Genome Sciences, Inc. (Rockville, MD) The Regents of the University of Michigan (Ann Arbor, MI) 2017-01-28 RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 8,329,179

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Citi
McKinsey
Deloitte
Julphar
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.